Thromboembolism - Pipeline Review, H2 2016

Date: July 20, 2016
Pages: 101
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: T1A7D7AF969EN
Leaflet:

Download PDF Leaflet

Thromboembolism - Pipeline Review, H2 2016

SUMMARY

Global Markets Direct’s, ‘Thromboembolism - Pipeline Review, H2 2016’, provides an overview of the Thromboembolism pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Thromboembolism, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Thromboembolism and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Thromboembolism
  • The report reviews pipeline therapeutics for Thromboembolism by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Thromboembolism therapeutics and enlists all their major and minor projects
  • The report assesses Thromboembolism therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Thromboembolism
REASONS TO BUY
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Thromboembolism
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Thromboembolism pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Thromboembolism Overview
Therapeutics Development
Pipeline Products for Thromboembolism - Overview
Pipeline Products for Thromboembolism - Comparative Analysis
Thromboembolism - Therapeutics under Development by Companies
Thromboembolism - Therapeutics under Investigation by Universities/Institutes
Thromboembolism - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Thromboembolism - Products under Development by Companies
Thromboembolism - Products under Investigation by Universities/Institutes
Thromboembolism - Companies Involved in Therapeutics Development
Bayer AG
Cereno Scientific AB
China Biologic Products, Inc.
Daiichi Sankyo Company, Limited
F. Hoffmann-La Roche Ltd.
Gamma Therapeutics, Inc.
GlycoMimetics, Inc.
Green Cross Corporation
Ionis Pharmaceuticals, Inc.
Portola Pharmaceuticals, Inc.
The International Biotechnology Center (IBC) Generium
Thromboembolism - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
alteplase biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
antithrombin III (human) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
betrixaban - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
C-3 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CS-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
edoxaban tosylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gammarin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GCC-2107 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GMI-1271 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IONIS-FXIRx - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Lysimab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptide to Inhibit PAI-1 for Arterial Thrombosis and Pulmonary Thromboembolism - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein for Thromboembolism - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rivaroxaban - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TAP-ANV - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TRX-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
YG-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Thromboembolism - Dormant Projects
Thromboembolism - Discontinued Products
Thromboembolism - Product Development Milestones
Featured News & Press Releases
May 27, 2016: Portola Pharmaceuticals Announces Full Results of Phase 3 APEX Study of Betrixaban Presented at International Society on Thrombosis and Haemostasis (ISTH) Meeting
May 23, 2016: Portola Pharmaceuticals Announces Upcoming Data Presentation on Betrixaban at International Society on Thrombosis and Haemostasis 2016 Scientific and Standardization Committee Meeting
Apr 06, 2016: Portola Pharmaceuticals Announces Presentation of Phase 3 APEX Study Results at International Society on Thrombosis and Haemostasis SSC Meeting 2016 on May 27, 2016
Mar 30, 2016: Bristol-Myers Squibb And Pfizer Announce Global Real-World Data Program And Present New Analyses Of Eliquis (Apixaban) At The American College Of Cardiology’S 65Th Annual Scientific Session
Mar 24, 2016: Portola Pharmaceuticals Announces Topline Results from Phase 3 APEX Trial of Betrixaban for Prevention of Blood Clots in Acute Medically Ill Patients
Dec 07, 2015: First Data Unveiled from CALLISTO Program Examining the Use of XARELTO (rivaroxaban) for Treating Blood Clots in People with Cancer
Nov 30, 2015: New Data from Bayer’s Portfolio in Thrombosis to be Presented at ASH 2015
Nov 06, 2015: Bristol-Myers Squibb and Pfizer to Present New Data on Eliquis (apixaban) at the American Heart Association Scientific Sessions 2015
Oct 30, 2015: Portola Pharmaceuticals Completes Enrollment in Pivotal Phase 3 APEX Study of Betrixaban for Prevention of Blood Clots in Acute Medically IllPatients
Oct 30, 2015: Isis Pharmaceuticals Initiates Phase 2 Study of ISIS-FXI Rx in Patients with End-Stage Renal Disease on Hemodialysis
Oct 13, 2015: Portola Pharmaceuticals Announces FDA Grants Fast Track Designation to Betrixaban for Prevention of Blood Clots in Acute Medically Ill Patients
Sep 24, 2015: Bayer’s Xarelto Approved in Japan for the Treatment and Secondary Prevention of Pulmonary Thromboembolism and Deep Vein Thrombosis
Sep 24, 2015: Bayer’s Xarelto Approved in Japan for the Treatment and Secondary Prevention of Pulmonary Thromboembolism and Deep Vein Thrombosis
Jul 12, 2015: NICE recommends edoxaban tosylate (Lixiana) for treating and preventing potentially fatal blood clots
Jun 18, 2015: Daiichi Sankyo Initiates Hokusai-VTE Cancer Study to Evaluate the Role of Edoxaban in Patients with Venous Thromboembolism Associated with Cancer
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Thromboembolism, H2 2016
Number of Products under Development for Thromboembolism - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Investigation by Universities/Institutes, H2 2016
Thromboembolism - Pipeline by Bayer AG, H2 2016
Thromboembolism - Pipeline by Cereno Scientific AB, H2 2016
Thromboembolism - Pipeline by China Biologic Products, Inc., H2 2016
Thromboembolism - Pipeline by Daiichi Sankyo Company, Limited, H2 2016
Thromboembolism - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
Thromboembolism - Pipeline by Gamma Therapeutics, Inc., H2 2016
Thromboembolism - Pipeline by GlycoMimetics, Inc., H2 2016
Thromboembolism - Pipeline by Green Cross Corporation, H2 2016
Thromboembolism - Pipeline by Ionis Pharmaceuticals, Inc., H2 2016
Thromboembolism - Pipeline by Portola Pharmaceuticals, Inc., H2 2016
Thromboembolism - Pipeline by The International Biotechnology Center (IBC) Generium, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Thromboembolism - Dormant Projects, H2 2016
Thromboembolism - Discontinued Products, H2 2016

LIST OF FIGURES

Number of Products under Development for Thromboembolism, H2 2016
Number of Products under Development for Thromboembolism - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Targets, H2 2016
Number of Products by Stage and Targets, H2 2016
Number of Products by Mechanism of Actions, H2 2016
Number of Products by Stage and Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016

COMPANIES MENTIONED

Bayer AG
Cereno Scientific AB
China Biologic Products, Inc.
Daiichi Sankyo Company, Limited
F. Hoffmann-La Roche Ltd.
Gamma Therapeutics, Inc.
GlycoMimetics, Inc.
Green Cross Corporation
Ionis Pharmaceuticals, Inc.
Portola Pharmaceuticals, Inc.
The International Biotechnology Center (IBC) Generium
Skip to top


Venous Thromboembolism - Pipeline Review, H2 2015 US$ 1,700.00 Nov, 2015 · 83 pages
Constipation - Pipeline Review, H2 2016 US$ 2,000.00 Jul, 2016 · 121 pages

Ask Your Question

Thromboembolism - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: